Safety of ultrashort-term sit with pollen allergoids adjuvanted by monophosphoryl lipid A: a prospective Italian survey.

A 3-year prospective post marketing survey on the safety of the recently developed ultrashort pre-seasonal subcutaneous immunotherapy (uSCIT-MPL4) with pollen allergoids adjuvanted with monophosphoryl lipid A was performed. A total of 510 patients received uSCIT-MPL4, 61% for grass, 35.7% for birch, 13.2% for parietaria and 3% for other pollens (ragweed, mugwort, and olive). A total of 3308 injections were given and the mean duration of uSCIT-MPL-4 was 2.3 years. Overall, only 7 slight systemic reactions (SR) were observed in 510 patients (1.37%) and 2.11/1000 injections suggesting that this treatment is even safer than traditional depot injection SIT.

[1]  M. Rosewich.  Ultra‐short course immunotherapy in children and adolescents during a 3‐yrs post‐marketing surveillance study , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[2]  G. Passalacqua,et al.  A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  R. Lockey,et al.  An update on the safety of specific immunotherapy , 2008, Current opinion in allergy and clinical immunology.

[4]  R. Dubakiene,et al.  Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN) , 2006, Allergy.

[5]  M. Jutel.  Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex® Quattro) , 2006, Drugs.

[6]  S. Woroniecki,et al.  Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. , 2003, Allergologia et immunopathologia.

[7]  F. Horak,et al.  A well‐tolerated grass pollen‐specific allergy vaccine containing
a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections , 2001, Allergy.

[8]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[9]  [WHO position paper. "Allergen immunotherapy: therapeutic vaccines for allergic diseases"]. , 1998, Arerugi = [Allergy].